Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocular Therapeutix reports strong Q4 performance and eyes pivotal trials

Ocular Therapeutix delivered a strong performance in Q4 2022, showcasing revenue growth and advancements in key product developments.
While facing financial challenges and the need for strategic partnerships, the company's solid cash position and product pipeline offer opportunities for future growth.
Investors should monitor Ocular Therapeutix's progress in pivotal trials, commercial expansion, and potential alliances to assess its long-term growth prospects.

Ocular Therapeutix progresses on OTX-TKI program and boosts sales

Ocular Therapeutix showcased advancements in its OTX-TKI program and DEXTENZA sales growth, while addressing financial performance.
Positive clinical trial updates and pricing strategy enhancements position the company for future growth.
Challenges include lack of operational spend guidance and uncertainties in study timelines, with opportunities in trial outcomes and market expansion.

Ocular Therapeutix reports record revenue, navigates pivotal trial funding

Ocular Therapeutix (OCUL) achieved record revenue with DEXTENZA and made significant progress in pipeline development.
While facing financial challenges and operational complexities, the company's strategic initiatives and leadership additions position it for future growth.
Advancements in trial designs, FDA interactions, and funding strategies offer avenues for enhancing product development and commercialization.

Ocular Therapeutix reports strong Q3 revenue growth and advances AMD treatment

Ocular Therapeutix's Q3 performance reflects revenue growth driven by DEXTENZA, with a focus on advancing wet AMD treatment through the OTX-TKI program.
While facing challenges in R&D expenses and trial enrollment criteria, the company is well-positioned with funding options and strategic partnerships.
Opportunities lie in expanding DEXTENZA's market presence, achieving pipeline milestones, and leveraging funding avenues for future growth and innovation.

Ocular Therapeutix excels in retinal focus, poised for leadership

Ocular Therapeutix is on a positive trajectory with advancements in key studies and a strong financial position. The company faces competition and regulatory challenges but has the potential to lead in retinal disease treatment with its innovative approach.

Ocular Therapeutix excels in AXPAXLI trials with FDA support

Ocular Therapeutix's Q3 2024 Earnings Call highlighted strong performance in trial enrollment and FDA support for AXPAXLI trials, backed by promising prior study results.
With solid financial positioning, active commercial efforts, and a strategic trial design, Ocular shows potential for success in the competitive ophthalmic market.
While facing challenges in differentiation, regulatory submissions, and operational complexities, Ocular can leverage opportunities for market acceptance and revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Expected to Enroll Approximately 300 Evaluable Subjects Primarily in the United States Expected to Enroll Approximately 300 Evaluable Subjects Primarily in the United States

Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

BeiGene

Bristol-Myers

Kezar Life Sciences Inc

Novartis

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a panel at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023 at 11:00 AM EDT.

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2023 Earnings Call Transcript August 7, 2023 4:30 PM ET Company Participants Antony Mattessich - President & CEO Donald Notman - CFO Rabia Ozden - CMO Steve Meyers - SVP, Commercial Conference Call Participants Dane Leone - RJF Jon Wolleben - JMP Joe Catanzaro - Piper Sandler Colleen Kusy - Baird Kelly Shi - Jefferies Tara Bancroft - TD Cowen Chaitanya G - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for standing by.

Ocular Therapeutix, Inc. (OCUL) Q2 2023 Earnings Call Transcript

DEXTENZA® Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24% Over Q2 2022 Closed on a New $82.5 million Credit Facility; Cash Runway Now Forecasted into 2025 First of Two Planned Pivotal Clinical Trials for OTX-TKI in Wet AMD Expected to Initiate in Q3 2023 Completed Enrollment of HELIOS U.S.-based OTX-TKI Phase 1 Clinical Trial for Treatment of Non-Proliferative Diabetic Retinopathy; 6-Month Interim Data Anticipated Q1 2024 Completed Enrollment of OTX-TIC Phase 2 Clinical Trial and Began Pilot Repeat-Dose Sub-Study BEDFORD, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the second quarter ended June 30, 2023, and provided updates on its ophthalmology pipeline.

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

BEDFORD, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced completion of enrollment in the HELIOS clinical trial of OTX-TKI.

Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that 12-month data from the U.S.-based Phase 1 trial evaluating OTX-TKI for the treatment of wet AMD will be presented at the 2023 Clinical Trials at the Summit Annual Meeting being held on June 10th in Park City, Utah. The Company will also participate in a panel discussing the challenges of bringing novel treatments to the market. Ocular Therapeutix is also sponsoring a presentation discussing the Company's proprietary bioresorbable hydrogel-based formulation technology and retina focused clinical programs. A conference call discussing the 12-month data from the U.S.-based Phase 1 clinical trial of OTX-TKI presented at the Clinical Trials at the Summit will be hosted by the Ocular Therapeutix management team on Monday, June 12th at 8:30 AM ET.

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 12:30 PM EDT at the Marriott Marquis in New York, NY.

Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference

Ocular Therapeutix, Inc. is up a lot since my last article. I am neutral to bearish because I don't see the molecule making a space for itself in the long-acting wet AMD space.

Ocular Therapeutix: I Still Don't See The Need

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q1 2023 Results Conference Call May 8, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Rabia Ozden - Chief Medical Officer Steve Meyers - Senior Vice President of Commercial Conference Call Participants Jon Wolleben - JMP Securities Joe Catanzaro - Piper Sandler Tara Bancroft - Cowen Colleen Kusy - Baird Yi Chen - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for standing by.

Ocular Therapeutix, Inc. (OCUL) Q1 2023 Earnings Call Transcript

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.

Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

12-month Top-Line Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented in June at the Clinical Trials at the Summit 2023 Meeting

Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update

BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:00 PM EDT at the New York Hilton Midtown in New York, NY.

Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference

BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held May 5-8 in San Diego, California.

Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

BEDFORD, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2023 financial results after the close on Monday, May 8, 2023. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company's financial results and provide a general business update.

Ocular Therapeutix™ To Report First Quarter 2023 Financial Results

BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held April 23 - 27 in New Orleans, Louisiana.

Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Steve Meyers - Senior Vice President of Commercial Rabia Ozden - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Jon Wolleben - JMP Securities Caroline Palomeque - Berenberg Joe Catanzaro - Piper Sandler Operator Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the Ocular Therapeutix Fourth Quarter and Year-End 2022 Earnings Conference Call.

Ocular Therapeutix, Inc. (OCUL) Q4 2022 Earnings Call Transcript

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and Degeneration Annual 2023 Meeting

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update

As a turnaround equity, Ocular Therapeutix, Inc. is showing signs of a successful comeback. OTX-TKI Phase 1 data for wet-AMD is quite robust.

Ocular Therapeutix: A Promising Turnaround Play

A promising report of a therapy in a phase 1 trial gave the stock a lift.

Why Shares of Ocular Therapeutix Jumped This Week

Ocular Therapeutix is a promising platform play poised to disruptively transform ophthalmology. Based on its innovative and validated hydrogel platform, Ocular can fill and expand its pipeline with unlimited new applications. With Dextenza, Ocular has an approved and profitable commercial product and is confident that its new strategy will accelerate its growth in 2023.

Next Round Of Financing Will Be Transformational For Ocular Therapeutix

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Ocular Therapeutix Stock (OCUL)